Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma-Reference-Cited by-同舟云学术

Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma

Published:2023-12 Issue:12 Volume:29 Page:757-762
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Pasvolsky Oren,Ghanem Sassine^ORCID,Milton Denái R.,Masood Adeel^ORCID,Tanner Mark R.,Bashir Qaiser,Srour Samer,Saini Neeraj,Lin Paul^ORCID,Ramdial Jeremy,Nieto Yago,Lee Hans C.,Patel Krina K.,Kebriaei Partow,Thomas Sheeba K.,Weber Donna M.,Orlowski Robert Z.,Shpall Elizabeth J.,Champlin Richard E.,Qazilbash Muzaffar H.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference24 articles.

1. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma;Joseph;J Clin Oncol,2020

2. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group;Sonneveld;Blood,2016

3. Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis;Scott;Biol Blood Marrow Transplant,2016

4. Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation;Kazmi;Clin Lymphoma Myeloma Leuk,2015

5. Mortality from multiple myeloma within one year following autologous stem cell transplantation: defining an ultra-high risk population;Cherniawsky;Clin Lymphoma Myeloma Leuk,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant;Blood Cancer Journal;2024-05-29

2. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma;BMC Cancer;2024-04-02

3. Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy;Frontiers in Oncology;2024-03-27

4. Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma;Cancer Science;2024-03-18

5. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience;Blood Cancer Journal;2024-01-10